Compare ESNT & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESNT | IONS |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.6B |
| IPO Year | 2013 | 1996 |
| Metric | ESNT | IONS |
|---|---|---|
| Price | $64.81 | $28.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 25 |
| Target Price | ★ $70.88 | $68.48 |
| AVG Volume (30 Days) | 711.3K | ★ 4.2M |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | 0.73 | ★ 21.71 |
| EPS | ★ 5.71 | N/A |
| Revenue | ★ $1,260,935,000.00 | N/A |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | N/A | $26.34 |
| P/E Ratio | $11.43 | ★ N/A |
| Revenue Growth | ★ 1.45 | N/A |
| 52 Week Low | $55.34 | $27.25 |
| 52 Week High | $71.84 | $86.74 |
| Indicator | ESNT | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 22.61 |
| Support Level | $63.62 | N/A |
| Resistance Level | $69.21 | $46.07 |
| Average True Range (ATR) | 1.84 | 2.07 |
| MACD | -0.31 | -1.18 |
| Stochastic Oscillator | 22.70 | 7.56 |
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).